February 22, 2022
In The News
Read Article
Noah Miller of Newsweek interviews Abraham Heifets, Atomwise CEO, about his Moonshot.
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.